Blogs
Developing a robust Pharmacokinetic (PK) assay for biotherapeutics often presents unforeseen biological hurdles. Occasionally, a traditional Ligand Binding Assay (LBA) may yield inconsistent data. In this particular case, the LBA assay was not reliably detecting drug in the matrix, potentially indicating some matrix stability issue during method development. In addition,…
March 22
- March 25
KCAS Bio will be exhibiting at the Society of Toxicology (SOT) Annual Meeting and ToxExpo, taking place in San Diego, California on March 22-25, 2026. As one of the largest gatherings of toxicologists and life sciences professionals, this event offers a unique platform to connect with leaders in toxicology and…
Blogs
Drug discovery is an essential part of the drug development process. Researchers test candidates to identify those suitable for regulated animal studies and, ultimately, clinical trials. Bioanalytical discovery involves assessing a compound’s physiochemical properties,…
webinars
As the field of biotherapeutics rapidly evolves, the development of advanced conjugated therapies such as Antibody-Drug Conjugates (ADCs), Antibody-RNA Conjugates (ARCs), siRNA/oligos, and antibody-peptide conjugates has gained significant momentum. These next-generation therapeutics offer promising efficacy and safety profiles for treating various conditions, including cancer, rare diseases, and in vaccine development.
Blogs
Understanding the intricate relationship between drugs and the human body is crucial for effective medical treatments. Two fundamental concepts in pharmacology – pharmacokinetics and pharmacodynamics – play pivotal roles in this understanding. This blog post will delve into these concepts, exploring their differences and significance in drug development and clinical…
Blogs
What is a generic PK assay? A generic pharmacokinetic (PK) assay, also referred to as a universal PK assay for New Biologic Entities (NBE), is used to measure circulating human biotherapeutics—primarily antibody-based—post-administration across various non-human matrices. These assays are particularly beneficial when drug-specific reagents, such as anti-idiotype antibodies, are…
Podcasts
Dom and John, the hosts of “The Weekly Bioanalysis”, recently returned from EBF in Barcelona where there was a session on Patient-centric Microsampling, which both of them found fascinating. This inspired both of them to decide it was high time to revisit this part of our industry. In spite of…
March 16
- March 20
KCAS Bio is excited to announce our participation in the Society of Toxicology (SOT) Annual Meeting and ToxExpo, taking place in Orlando, Florida on March 16th-20th. As one of the largest gatherings of toxicologists and life sciences professionals, this event offers a unique platform to connect with leaders in toxicology…
Podcasts
In episode 84 of “The Weekly Bioanalysis”, our special guest, Bryan Parmentier, joins Dom and John to discuss his background and current role at KCAS Bio, offering insights into the field of small molecule method development. He delves into the typical challenges encountered when working with LC-MS analytes, and how…
Blogs
The Role of Pharmacokinetics (PK) in Drug R&D Pharmacokinetics (PK) is defined as the study of the fate of a new therapeutic entity (NTE) after it is administered into the body of animals or humans. It involves understanding how the drug is absorbed, distributed, metabolized, and eliminated (ADME). Essentially, PK…
Podcasts
Our hosts, Dom and John, are excited to welcome special guest, Carrie Vyhlidal, to discuss the topic of the 80th episode of “The Weekly Bioanalysis” podcast – The Rapid Evolution of PCR Assays. PCR (or Polymerase Chain Reaction) is like a copying machine for DNA. Scientists have found ways to…
Podcasts
The most recent episode of “The Weekly Bioanalysis” podcast is all about genes! The topic was originally inspired by an article entitled “The Coming of Age of One-and-Done Therapies” which jumped out to both of our hosts, Dom and John, and had been on the back burner for a while…